The Etiology and Pathogenesis of Benign Prostatic Hyperplasia: The Roles of Sex Hormones and Anatomy

Overview

Journal Res Rep Urol

Publisher Dove Medical Press

Specialty Urology

Date 2024 Sep 30

PMID 39345801

Authors

Ganzhe Xu

Guoyu Dai

Zhongli Huang

Qiunong Guan

Caigan Du

Xiaoming Xu

Affiliations

Soon will be listed here.

Abstract

Benign prostatic hyperplasia (BPH) mainly causes lower urinary tract symptoms in ageing men, but its exact etiology and pathogenesis have not been established. The objective of this review was to design an update on the advances of human BPH research. We undertook a literature search for identifying studies of the roles of sex hormones (androgens and estrogens) in the onset and development of human BPH using the Pubmed database. In literature, many studies have indicated that ageing and obesity are the factors for preceding the onset of BPH. No evidence for the role of testosterone (T) or dihydrotestosterone (DHT) is found in BPH initiation. Since BPH exclusively occurs in the transitional zone (TZ) surrounding the urethra, it is postulated that years of exposure to uncharacterized urinary toxins could disrupt the homeostasis of the stroma and/or epithelium of this prostatic zone that are typically occurring in ageing men. After cellular damage and subsequent inflammation generated, the intraprostatic DHT produced mainly from T by 5α-reductase promotes BPH development. Further, estrogens could take part in the nodular proliferation of stromal cells in some BPH patients. The confounding of BPH may attenuate the development of prostate tumor in the TZ. In conclusion, evidence in literature suggests that androgens are not etiological factors for BPH, and intraprostatic DHT along with chronic inflammation are mainly responsible for nodular proliferation of stromal and/or epithelial cells in prostatic TZ. The urinary factors for the etiology of BPH and BPH as a prediction of PCa progression still need further investigation.

References

Page S, Lin D, Mostaghel E, Hess D, True L, Amory J . Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab. 2006; 91(10):3850-6. DOI: 10.1210/jc.2006-0968. View

Xia B, Zhao S, Chen Z, Chen C, Liu T, Yang F . Relationship between serum total testosterone and prostate volume in aging men. Sci Rep. 2021; 11(1):14122. PMC: 8266836. DOI: 10.1038/s41598-021-93728-1. View

Saffarini C, McDonnell E, Amin A, Spade D, Huse S, Kostadinov S . Maturation of the developing human fetal prostate in a rodent xenograft model. Prostate. 2013; 73(16):1761-75. PMC: 4306740. DOI: 10.1002/pros.22713. View

Banerjee P, Banerjee S, Brown T, Zirkin B . Androgen action in prostate function and disease. Am J Clin Exp Urol. 2018; 6(2):62-77. PMC: 5902724. View

Roberts R, Jacobson D, Rhodes T, Klee G, Leiber M, Jacobsen S . Serum sex hormones and measures of benign prostatic hyperplasia. Prostate. 2004; 61(2):124-31. DOI: 10.1002/pros.20080. View

Idan A, Griffiths K, Harwood D, Seibel M, Turner L, Conway A . Long-term effects of dihydrotestosterone treatment on prostate growth in healthy, middle-aged men without prostate disease: a randomized, placebo-controlled trial. Ann Intern Med. 2010; 153(10):621-32. DOI: 10.7326/0003-4819-153-10-201011160-00004. View

Yin M, Bastacky S, Chandran U, Becich M, Dhir R . Prevalence of incidental prostate cancer in the general population: a study of healthy organ donors. J Urol. 2008; 179(3):892-5. DOI: 10.1016/j.juro.2007.10.057. View

Marinello M, Montes M, FARNSWORTH W, Hare D, Fisher B, Bannerman R . Benign prostatic hyperplasia in an XX man. Urology. 1979; 13(6):640-5. DOI: 10.1016/0090-4295(79)90387-x. View

Bosch R . Pathogenesis of benign prostatic hyperplasia. Eur Urol. 1991; 20 Suppl 1:27-30. DOI: 10.1159/000471742. View

10.

Davey R, Grossmann M . Androgen Receptor Structure, Function and Biology: From Bench to Bedside. Clin Biochem Rev. 2016; 37(1):3-15. PMC: 4810760. View

11.

Grayhack J, Smith N, Ilio K, Wambi C, Kasjanski R, Crawford S . Pigment epithelium-derived factor, a human testis epididymis secretory product, promotes human prostate stromal cell growth in culture. J Urol. 2003; 171(1):434-8. DOI: 10.1097/01.ju.0000088774.80045.c4. View

12.

Wang Y, Yang L, Deng Y, Yan S, Luo L, Chen P . Causal relationship between obesity, lifestyle factors and risk of benign prostatic hyperplasia: a univariable and multivariable Mendelian randomization study. J Transl Med. 2022; 20(1):495. PMC: 9617448. DOI: 10.1186/s12967-022-03722-y. View

13.

Okada K, Miyake H, Ishida T, Sumii K, Enatsu N, Chiba K . Improved Lower Urinary Tract Symptoms Associated With Testosterone Replacement Therapy in Japanese Men With Late-Onset Hypogonadism. Am J Mens Health. 2016; 12(5):1403-1408. PMC: 6142172. DOI: 10.1177/1557988316652843. View

14.

Andriole G, Bruchovsky N, Chung L, Matsumoto A, Rittmaster R, Roehrborn C . Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia. J Urol. 2004; 172(4 Pt 1):1399-403. DOI: 10.1097/01.ju.0000139539.94828.29. View

15.

Yamana K, Labrie F, Luu-The V . Human type 3 5α-reductase is expressed in peripheral tissues at higher levels than types 1 and 2 and its activity is potently inhibited by finasteride and dutasteride. Horm Mol Biol Clin Investig. 2015; 2(3):293-9. DOI: 10.1515/HMBCI.2010.035. View

16.

Dehm S, Tindall D . Molecular regulation of androgen action in prostate cancer. J Cell Biochem. 2006; 99(2):333-44. DOI: 10.1002/jcb.20794. View

17.

Labrie F . Adrenal androgens and intracrinology. Semin Reprod Med. 2005; 22(4):299-309. DOI: 10.1055/s-2004-861547. View

18.

Untergasser G, Madersbacher S, Berger P . Benign prostatic hyperplasia: age-related tissue-remodeling. Exp Gerontol. 2005; 40(3):121-8. DOI: 10.1016/j.exger.2004.12.008. View

19.

Swerdloff R, Dudley R, Page S, Wang C, Salameh W . Dihydrotestosterone: Biochemistry, Physiology, and Clinical Implications of Elevated Blood Levels. Endocr Rev. 2017; 38(3):220-254. PMC: 6459338. DOI: 10.1210/er.2016-1067. View

20.

Augustin H, Erbersdobler A, Graefen M, Fernandez S, Palisaar J, Huland H . Biochemical recurrence following radical prostatectomy: a comparison between prostate cancers located in different anatomical zones. Prostate. 2003; 55(1):48-54. DOI: 10.1002/pros.10216. View